Major Program
Supportive Care and Symptom Management
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
Sponsor
Alliance for Clinical Trials in Oncology
Status
Completed
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT03578081
This randomized phase III trial studies how well olanzapine with or without fosaprepitant
work in preventing chemotherapy induced nausea and vomiting in cancer patients receiving
chemotherapy that causes vomiting. Olanzapine and fosaprepitant dimeglumine may help control
nausea and vomiting in patients during chemotherapy. Olanzapine is usually given in
combination with other drugs, including fosaprepitant dimeglumine. It is not yet known if
olanzapine when given with other drugs, is still effective without using fosaprepitant
dimeglumine for controlling nausea and vomiting.
work in preventing chemotherapy induced nausea and vomiting in cancer patients receiving
chemotherapy that causes vomiting. Olanzapine and fosaprepitant dimeglumine may help control
nausea and vomiting in patients during chemotherapy. Olanzapine is usually given in
combination with other drugs, including fosaprepitant dimeglumine. It is not yet known if
olanzapine when given with other drugs, is still effective without using fosaprepitant
dimeglumine for controlling nausea and vomiting.
Intervention
Palonosetron Hydrochloride, Ondansetron Hydrochloride, Dexamethasone, Fosaprepitant Dimeglumine, Olanzapine, Placebo
Condition
Malignant Neoplasm
Investigators
Rudolph Navari, MD, PhD, FACP